Li Q, Luo H, Dai FQ, Wang RT, Fan XQ, Luo YY, Deng MS, Wang Y, Long T, Guo W, Xu B*, Xu CX*, Jin H*. SAMD9 promotes postoperative recurrence of esophageal squamous cell carcinoma by stimulating MYH9-mediated GSK3β/β-catenin signaling. Adv Sci. 2023, Feb 9, e2203573 (IF:17.5)
Li Q, Deng MS, Wang RT, Luo H, Luo YY, Zhang DD, Chen KJ, Cao XF, Yang GM, Zhao TM, Xu B, Xu CX*, Wang JM*. PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation. Pharmacol Res. 2023,187:106636 (IF: 10.3)
Luo H, Shan J, Zhang H, Song G, Li Q*, Xu CX*. Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer. Semin Cancer Biol. 2022，86：960-70. (IF：17.0)
Li Q, Luo H, Luo YY, Zahng W, Hong HM, Deng MS, Wang Y, Xu B, Song GB*, Xu CX*. Plumbagin-loaded ZIF-90 nanoparticles suppress gastric cancer progression by targeting the YAP1 signaling. Chem Eng J. 2022, 437:135369 (IF：16.7)
Li Q, Zhou ZW, Lu J, Luo H, Wang SN, Peng Y, Deng MS, Song GB, Wang JM, Wei X, Wang JM, Wei X, Wang D*, Westrover KD*, Xu CX*. PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer. Mol Ther. 2022, 30:621-631. (IF：12.9）
Li Q, Zhou ZW, Duan W, Qian CY, Wang SN, Zi D, Wang JM, Mao CY, Song G, Wang D*, Westover KD*, Xu CX*. Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT. J Exp Clin Cancer Res. 2021, 40:220. (IF：12.7)
Zhou ZW, Ambrogio C, Bera AK*, Li Q, Li XX, Li L, Son J, Gondi S, Li J, Campbell E, Jin H, Okoro JJ, Xu CX*, Janne PA*, Westover KD*. KRASQ61 preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer. Cancer Res. 2020, 80:3719-3731 (IF：13.3)
Jin H, Jang Y, Cheng N, Li Q, Cui PF, Zhou ZW, Jiang HL, Westover KD, Tan QY, and Xu CX. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression. J Exp Clin Cancer Res. 2019, 38(1):165 (IF：12.7)
Zhang L, Huang P, Li Q, Wang D, and Xu CX. miR-134-5p promotes stage Ⅰlung adenocarcinoma metastasis and chemoresistance by targeting DAB2. Mol Ther. Nucleic Acids. 2019, 18: 627-637. (IF：10.2)
Jin H, Li DW, Wang SN, Luo S, Li Q, Huang P, Wang JM, Xu M, Xu CX. miR-125a promotes the progression of giant cell tumors of bone by stimulating IL-17A and β-catenin expression. Mol Ther. Nucleic Acids. 2018, 13: 493-502. (IF：10.2)
